These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6636255)

  • 1. Kinetic predictive techniques applied to lignocaine therapeutic drug monitoring.
    Joel SE; Bryson SM; Small M; Hillis WS; Kelman AW; Whiting B
    Ther Drug Monit; 1983; 5(3):271-7. PubMed ID: 6636255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid prediction of individual dosage requirements for lignocaine.
    Vozeh S; Berger M; Wenk M; Ritz R; Follath F
    Clin Pharmacokinet; 1984; 9(4):354-63. PubMed ID: 6467768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lignocaine kinetics in cardiac patients and aged subjects.
    Nation RL; Triggs EJ; Selig M
    Br J Clin Pharmacol; 1977 Aug; 4(4):439-48. PubMed ID: 901735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma lignocaine concentrations associated with extradural analgesia in patients with and without multiple organ failure.
    Putensen C; Lingnau W; Putensen-Himmer G; Herold M
    Br J Anaesth; 1992 Nov; 69(5):513-6. PubMed ID: 1467084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of lignocaine in children following caudal anaesthesia.
    Ecoffey C; Desparmet J; Berdeaux A; Maury M; Giudicelli JF; Saint-Maurice C
    Br J Anaesth; 1984 Dec; 56(12):1399-402. PubMed ID: 6498050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient comfort and plasma lignocaine concentrations during fibreoptic bronchoscopy.
    Sutherland AD; Santamaria JD; Nana A
    Anaesth Intensive Care; 1985 Nov; 13(4):370-4. PubMed ID: 4073449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors affecting free (unbound) lignocaine concentration in suspected acute myocardial infarction.
    Routledge PA; Stargel WW; Barchowsky A; Wagner GS; Shand DG
    Br J Clin Pharmacol; 1989 Nov; 28(5):593-7. PubMed ID: 2590613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function.
    Orlando R; Piccoli P; De Martin S; Padrini R; Palatini P
    Br J Clin Pharmacol; 2003 Jan; 55(1):86-93. PubMed ID: 12534644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood concentration of lignocaine after application of 2% lignocaine gel in the urethra.
    Axelsson K; Jozwiak H; Lingårdh G; Schönebeck J; Widman B
    Br J Urol; 1983 Feb; 55(1):64-8. PubMed ID: 6824867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of lignocaine.
    Benowitz NL; Meister W
    Clin Pharmacokinet; 1978; 3(3):177-201. PubMed ID: 350470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of individual dosage requirements for lignocaine: a validation study for Bayesian forecasting in Japanese patients.
    Uematsu T; Hirayama H; Nagashima S; Yamazaki T; Tsuchiya N; Sato R; Nakashima M
    Ther Drug Monit; 1989; 11(1):25-31. PubMed ID: 2911849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lignocaine: a new technique for intravenous administration.
    Levy RA; Charuzi Y; Mandel WJ
    Br Heart J; 1977 Sep; 39(9):1026-8. PubMed ID: 907767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The appropriate dosage regime for the transition from intravenous lignocaine to oral tocainide after acute myocardial infarction.
    Upward JW; Holt D; Emery P; Akhras F; Jackson G
    Eur J Clin Pharmacol; 1983; 25(5):589-94. PubMed ID: 6420162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of propranolol and pindolol on plasma lignocaine clearance in man.
    Svendsen TL; Tangø M; Waldorff S; Steiness E; Trap-Jensen J
    Br J Clin Pharmacol; 1982; 13(Suppl 2):223S-226S. PubMed ID: 7104144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein binding and disposition of lignocaine in the elderly.
    Cusack B; O'Malley K; Lavan J; Noel J; Kelly JG
    Eur J Clin Pharmacol; 1985; 29(3):323-9. PubMed ID: 4076329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma lignocaine levels during transurethral prostatectomy.
    Eardley I; Broome GD; Murray A; Ramsay JW; Whitfield HN; Wilkinson DJ
    Ann R Coll Surg Engl; 1989 Sep; 71(5):278-80. PubMed ID: 2802473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma concentrations of lignocaine during fibreoptic bronchoscopy.
    Efthimiou J; Higenbottam T; Holt D; Cochrane GM
    Thorax; 1982 Jan; 37(1):68-71. PubMed ID: 7071796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lignocaine and indocyanine green kinetics in patients following myocardial infarction.
    Bax ND; Tucker GT; Woods HF
    Br J Clin Pharmacol; 1980 Oct; 10(4):353-61. PubMed ID: 7448106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Logical approach to lignocaine therapy.
    Aps C; Bell JA; Jenkins BS; Poole-Wilson PA; Reynolds F
    Br Med J; 1976 Jan; 1(6000):13-5. PubMed ID: 1247716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure.
    Prescott LF; Adjepon-Yamoah KK; Talbot RG
    Br Med J; 1976 Apr; 1(6015):939-41. PubMed ID: 1268491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.